Description
Release form
Chewable tablets.
Packing
28 pcs.
Pharmacological action
Montelar is a blocker of cysteinyl leukotriene receptors CysLT1 (leukotrienes C4, D4 and E4 are mediators of chronic persistent inflammation that supports bronchial hyperresponsiveness in asthma).
Prevents excessive secretion in the bronchi, swelling of the mucous membrane of the respiratory tract. Reduces the severity of bronchial asthma and the frequency of asthmatic attacks. Highly effective when taken orally.
Bronchodilator action develops within 1 day and lasts a long time.
Effective in patients with mild persistent asthma, not sufficiently controlled by bronchodilators alone.
Contraindications
Hypersensitivity, children’s age (up to 6 years).
Caution. Pregnancy, lactation.
Special instructions
It is recommended that you continue to take it after you have achieved a significant improvement.
Should not be used to relieve acute asthmatic attacks, does not replace inhaled bronchodilators.
Composition
1 tablet contains:
Active ingredient: montelukast sodium – 5.2 MG, which corresponds to the content of montelukast – 5 mg
Excipients: mannitol – 194.9 mg, microcrystalline cellulose – 66 mg, croscarmellose sodium – 15 mg, hyprolose (ty EXF) – 9 mg cherry flavoring – 2.4 mg (contains 0. 07% of charming red dye Allura red AC (E129)), aspartame – 1.2 mg, cherry flavor – 0.6 mg, dye of iron (III) oxide red – 0.45 mg, magnesium stearate – 5.25 mg.
Dosage and administration
Children 6-14 years old – 5 mg / day (one chewable tablet).
Side effects
Abdominal pain, headache, nausea, flu-like syndrome, cough, sinusitis, pharyngitis, increased activity of hepatic transaminases, allergic reactions.
Drug Interactions
Montelukast can be prescribed together with other drugs, traditionally used for the prevention and long-term treatment of bronchial asthma, such as bronchodilators and inhaled corticosteroids.
When a therapeutic effect is achieved with montelukast therapy, the dose of bronchodilators and corticosteroids can be gradually reduced.
The dose of corticosteroids should be reduced gradually, under the supervision of a physician. In some patients, inhaled corticosteroids may be completely canceled. A sharp replacement of inhaled corticosteroids therapy with montelukast is not recommended.
The recommended therapeutic dose of montelukast did not have a clinically significant effect on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (ethinyl estradiol / norethindrone 35/1), terfenadine, digoxin and warfarin. AUC decreases in individuals simultaneously receiving phenobarbital (approximately 40%), however, correction of the dosage regimen of montelukast to such patients is not required.
In vitro studies have shown that montelukast is a potential inhibitor of the CYP2C8 isoenzyme, however, clinical trials of the drug-drug interaction, including montelukast and rosiglitazone (a preliminary substrate of a representative of drugs that are primarily metabolized by CYP2C8 isoenzyme), have shown that doses of montelukast8 do not inhibit in vivo. Therefore, montelukast does not significantly affect the metabolism of drugs metabolized by this enzyme (e.g. paclitaxel, rosiglitazone and repaglinide).
Since montelukast is metabolized by the CYP3A4 isoenzyme, caution should be exercised (especially in children) if montelukast is given simultaneously with drugs. inducing CYP3A4 isoenzyme, such as phenytoin, phenobarbital and rifampicin.
Overdose
There are no data on overdose symptoms when taking montelukast in patients with bronchial asthma in a dose exceeding 200 mg / day for 22 weeks and at a dose of 900 mg / day for 1 week.
There are reports of acute overdose of montelukast in children (taking the drug at least 1000 mg / day). Clinical and laboratory data in this case indicate the compliance of the safety profile of montelukast in children with the safety profile in adults and elderly patients.
Symptoms: the most common are thirst, drowsiness, vomiting, mydriasis, hyperkinesis, psychomotor agitation, headache and abdominal pain.
Treatment: symptomatic treatment. There is no data on the possibility of excretion of montelukast by peritoneal dialysis or hemodialysis.
Storage Conditions
In a place protected from light and moisture, at a temperature not exceeding 30 ° C.
Keep out of the reach and sight of children.
Expiration
2 years.
active substance
Montelukast
Terms leave through pharmacies
In retseptu
dosage form
resuscitation pills
For
For adults as prescribed by a doctor, For children prescribed by a doctor, Children over 2 years old
Indications
Indications
bronchospasm, allergic rhinitis
